论文部分内容阅读
目的探讨米非司酮联合桂枝茯苓丸治疗子宫肌瘤的临床疗效。方法选取2014年9月至2016年5月间昌江黎族自治县妇幼保健院收治的100例子宫肌瘤患者为研究对象,采用抽签方式分为观察组和对照组,每组50例,观察组患者采用米非司酮联合桂枝茯苓丸治疗,对照组患者采用米非司酮治疗。结果治疗后,观察组患者肿瘤坏死因子-α(TNF-α)水平为(0.30±0.21)ng/L、超敏C-反应蛋白(hs-CRP)水平为(1.52±1.32)mg/L、CA125水平为(12.63±2.01)U/ml、CA199水平为(16.54±2.32)U/ml、人附睾蛋白4(HE4)水平为(30.14±1.58)pmol/L和治疗总有效率(92.0%)明显优于对照组患者TNF-α水平值(1.68±1.89)ng/L、hs-CRP水平值(6.74±1.65)mg/L、CA125水平值(40.45±2.14)U/ml、CA199水平值(32.14±2.89)U/ml、HE4水平值(55.62±2.63)pmol/L和治疗总有效率(58.0%),两组比较差异均有统计学意义(均P<0.05)。结论米非司酮联合桂枝茯苓丸治疗子宫肌瘤患者效果显著。
Objective To investigate the clinical efficacy of mifepristone combined with Guizhi Fuling capsule in the treatment of uterine fibroids. Methods From September 2014 to May 2016, 100 cases of uterine fibroids in Changjiang Li Autonomous County Maternal and Child Health Hospital were enrolled in this study. The patients were divided into observation group and control group by lottery. Each group included 50 patients in observation group Mifepristone and Guizhi Fuling pill treatment, the control group of patients treated with mifepristone. Results After treatment, the level of tumor necrosis factor-α (TNF-α) in observation group was (0.30 ± 0.21) ng / L and the level of hs-CRP was (1.52 ± 1.32) mg / The CA125 level was (12.63 ± 2.01) U / ml, the CA199 level was (16.54 ± 2.32) U / ml, the level of HE4 was (30.14 ± 1.58) pmol / L and the total effective rate was 92.0% (1.68 ± 1.89) ng / L, hs-CRP level (6.74 ± 1.65) mg / L, CA125 level (40.45 ± 2.14) U / ml, CA199 level 32.14 ± 2.89) U / ml, HE4 level (55.62 ± 2.63) pmol / L and total effective rate (58.0%). There were significant differences between the two groups (all P <0.05). Conclusion The combination of mifepristone and Guizhi Fuling capsule has a significant effect on patients with uterine fibroids.